Investigating how chemotherapy and immune therapy work together in lung cancer treatment
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence
This study is looking at how combining chemotherapy with special immune treatments might work better for people with advanced lung cancer, by helping the immune system fight the cancer more effectively.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10871844 on NIH RePORTER |
What this research studies
This research explores the effectiveness of combining chemotherapy with T cell checkpoint inhibitors in treating metastatic non-small cell lung cancer. It aims to understand the underlying mechanisms that make this combination more effective than traditional treatments. The study focuses on how chemotherapy can induce a state called cellular senescence, which may enhance the immune system's ability to fight cancer. By examining these processes, the research seeks to identify new treatment strategies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic non-small cell lung cancer who are considering treatment options.
Not a fit: Patients with early-stage lung cancer or those who do not have non-small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for lung cancer patients, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating that combining chemotherapy with immune therapies can enhance treatment efficacy.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Bott, Matthew J — Sloan-Kettering Inst Can Research
- Study coordinator: Bott, Matthew J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.